Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine effects on plasma hydrogen sulfide in chronic kidney disease and dialysis
NL-OMON36609Phase 3Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of acetylcysteine in chronic kidney disease (CKD) (4 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Plasma hydrogen sulfide levels. Started Jul 2011; status: active, not recruiting.
02
Drugs
acetylcysteine
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON36609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36609.